COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

bioRxiv posts many COVID19-related papers. A reminder: they have not been formally peer-reviewed and should not guide health-related behavior or be reported in the press as conclusive.

24,521 Articles (18,646 medRxiv, 5,875 bioRxiv)

Most recent first Previous |  Page 14: Articles 131-140  | Next

The COVID-19 pandemic impact on continuity of care provision on rare brain diseases and on Ataxia, Dystonia and PKU. A scoping review protocol
Cannizzo, S., Quoidbach, V., Giunti, P., Oertel, W., Pastores, G., Relja, M., Turchetti, G.
10.1101/2022.07.26.22277799 — Posted: 2022-07-29
The Association of Socioeconomic Status, the Concern for Catching Covid-19, and Anxiety Between Individuals with and without a Cancer History from a Cross-sectional Study
Zhang, X., Impact of COVID-19 on Behaviors across the Cancer Control Continuum in Ohio group, , Sasmal, S., Yu, M., Bernardo, B., Adeyanju, T., Paskett, E.
10.1101/2022.07.26.22278080 — Posted: 2022-07-29
Computer Simulation of the interaction between SARS-CoV-2 Spike Protein and the Surface of Coinage Metals
Sahihi, M., Faraudo, J.
10.1101/2022.07.28.501856 — Posted: 2022-07-29
Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of mRNA vaccine
Xie, X., Zou, J., Liu, M., Ren, P., Shi, P.-Y.
10.1101/2022.07.29.502055 — Posted: 2022-07-29
A multispecific antibody confers pan-reactive SARS-CoV-2 neutralization and prevents immune escape
Misasi, J., Wei, R. R., Wang, L., Pegu, A., Wei, C.-J., Oloniniyi, O., Zhou, T., Zhao, B., Choe, M., Boruszczak, M., Chen, M., Leung, K., Li, J., Yang, E. S., Yang, Z.-Y., Zhang, Y., Carlton, K., Harris, D. R., Ivleva, V. B., Lei, P., Liu, C., Longobardi, L., Olia, A. S., Shi, W., Wolff, J. J., Gall, J., Koup, R. A., Kwong, P. D., Mascola, J. R., Nabel, G. J., Sullivan, N. J.
10.1101/2022.07.29.502029 — Posted: 2022-07-29
Psychological impacts of COVID-19 outbreak in Ethiopia: a systematic review and meta-analysis
Lankrew, T., Gelaw, B.
10.1101/2022.07.27.22278107 — Posted: 2022-07-29
Effect of Delta and Omicron mutations on the RBD-SD1 do-main of the Spike protein in SARS-CoV-2 and the Omicron mutations on RBD-ACE2 interface complex
Ching, W.-Y., Adhikari, P., Jawad, B., Podgornik, R.
10.1101/2022.07.28.501901 — Posted: 2022-07-28
P2G3 human monoclonal antibody neutralizes SARS-CoV-2 Omicron subvariants including BA.4 and BA.5 and Bebtelovimab escape mutants
Turelli, P., Fenwick, C., Raclot, C., Genet, V., Pantaleo, G., Trono, D.
10.1101/2022.07.28.501852 — Posted: 2022-07-28
Molecular basis for antiviral activity of pediatric neutralizing antibodies targeting SARS-CoV-2 Spike receptor binding domain
Chen, Y., Prevost, J., Ullah, I., Romero, H., Lisi, V., Tolbert, W. D., Grover, J. R., Ding, S., Gong, S. Y., Beaudoin-Bussieres, G., Gasser, R., Benlarbi, M., Vezina, D., Anand, S. P., Chatterjee, D., Goyette, G., Grunst, M. W., Yang, Z., Bo, Y., Zhou, F., Beland, K., Bai, X., Zeher, A. R., Huang, R. K., Nguyen, D. N., Sherburn, R., Wu, D., Piszczek, G., Pare, B., Matthies, D., Xia, D., Richard, J., Kumar, P., Mothes, W., Cote, M., Uchil, P. D., Lavallee, V.-P., Smith, M. A., Pazgier, M., Haddad, E., Finzi, A.
10.1101/2022.07.27.501708 — Posted: 2022-07-28
Development of Equine Polyclonal Antibodies as a Broad-Spectrum Therapy Against SARS-CoV-2 Variants
Liao, S., He, Y., Qu, J., Shi, Y., Liu, Y., Zhao, K., Chen, J., Jing, Y., Shen, C. K.-F., Ji, C., Luo, G., Zhao, X., Li, S., Fan, Y., Lv, Z., Fang, S., He, Y., Wu, C., Zhang, R., Zou, X., Wang, P., Li, L.
10.1101/2022.07.27.501719 — Posted: 2022-07-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).